SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

LOQTORZI

CHRS·Coherus Oncology, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the U.S. since October 2023.
Why 4/10
LOQTORZI is already FDA-approved and commercially launched for nasopharyngeal carcinoma, so there is no pending PDUFA or pivotal readout for this drug itself. The next hard catalyst is the expedited development path for the tagmokitug/toripalimab combination in esophageal cancer, but that is an investigational combination (tagmokitug is not yet approved), not a binary event for LOQTORZI alone. No single upcoming binary catalyst for LOQTORZI within the next 12 months.
Actionable Insight NEUTRAL

LOQTORZI is a commercial-stage asset generating growing but still modest revenue (Q2 2026 net sales of $13.6M, up 15% sequentially). The company reported Q3 2026 results on November 9, 2026 with a $39.3M net loss and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer. Watch for Q3 LOQTORZI revenue trajectory and any updates on the expedited esophageal cancer development path. The stock trades near $0.84, down from a 52-week high of $2.62, reflecting the company's cash burn and pipeline-stage focus beyond LOQTORZI.

Price Chart

Loading chart...

Executive Summary

LOQTORZI (toripalimab-tpzi) is an FDA-approved PD-1 inhibitor marketed by Coherus Oncology (NASDAQ: CHRS) for nasopharyngeal carcinoma (NPC). It was approved in October 2023 as the first China-developed PD-1 inhibitor to receive U.S. approval, and the only FDA-approved treatment specifically for NPC. Coherus licensed U.S. rights from Shanghai Junshi Biosciences. LOQTORZI is commercially launched with growing revenue (Q2 2026 net sales of $13.6M, up 15% sequentially), and management has guided for $57M-$62M in full-year 2026 LOQTORZI revenue and peak sales of $150M-$200M by mid-2028. The drug is also being studied in combination with Coherus' pipeline assets (tagmokitug, casdozokitug) in other cancers. On November 9, 2026, Coherus reported Q3 results with a $39.3M net loss and announced a strategic prioritization plan focusing on the tagmokitug/toripalimab combination in esophageal cancer.

How It Works

LOQTORZI is a PD-1 inhibitor, a type of immunotherapy. PD-1 is a protein on immune cells that acts as a brake, preventing them from attacking cancer cells. LOQTORZI blocks PD-1, releasing the brake and allowing the immune system to recognize and destroy cancer cells. It is described as a "next-generation" PD-1 inhibitor and was the first China-developed PD-1 inhibitor to receive FDA approval.

Trial Status

LOQTORZI (toripalimab-tpzi) was approved by the FDA in October 2023 for the first-line treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine, and as a single agent for recurrent/metastatic NPC after progression on platinum-based chemotherapy. The approval was based on the Phase 3 JUPITER-02 study and Phase 2 POLARIS-02 study. Six-year follow-up data from JUPITER-02 showed median overall survival of 64.8 months with LOQTORZI plus chemotherapy versus chemotherapy alone, nearly doubling survival. Coherus is also evaluating toripalimab in combination with its investigational CCR8 antibody tagmokitug in esophageal cancer and other solid tumors, with interim data reported in October 2026.

The Two-Sided Case

▲ Bull Case5
LOQTORZI is the only FDA-approved treatment specifically for nasopharyngeal carcinoma, a niche with limited competition and a clear medical need.
Six-year JUPITER-02 follow-up data showed LOQTORZI plus chemotherapy nearly doubled median overall survival (64.8 months vs chemotherapy alone), with a 38% lower risk of death.
Revenue is growing: Q2 2026 LOQTORZI net sales of $13.6M were up 15% sequentially and 92% year-over-year, with management guiding $57M-$62M for full-year 2026.
NCCN guidelines list LOQTORZI as a Preferred Category 1 regimen for first-line NPC, providing strong clinical endorsement.
The drug serves as a backbone for Coherus' pipeline combinations (tagmokitug, casdozokitug, ZM008), potentially expanding its addressable market beyond NPC.
▼ Bear Case6
NPC is a rare cancer, limiting LOQTORZI's peak sales potential to an estimated $150M-$200M by mid-2028, which is modest for a commercial biotech.
The PD-1 inhibitor market is intensely competitive, dominated by Merck's Keytruda and Bristol Myers' Opdivo, which have broad label approvals across many cancer types.
Coherus priced LOQTORZI at a roughly 20% discount to Keytruda, suggesting pricing pressure in the PD-1 class.
Coherus reported a Q3 2026 net loss of $39.3M and the stock trades near $0.84, down sharply from its 52-week high of $2.62, reflecting ongoing cash burn and investor skepticism.
The company's strategic pivot to tagmokitug/toripalimab in esophageal cancer is early-stage (interim data only), with no guarantee of regulatory success or commercial viability.
Multiple tracked institutional investors trimmed or nearly exited CHRS positions in Q2 2026 (SEI, Millennium, Citadel, Susquehanna all reduced holdings significantly).

Upcoming Catalysts

  • Q3 2026 LOQTORZI revenue and commercial update (reported November 9, 2026, after close).
  • Expedited development path for tagmokitug/toripalimab combination in esophageal cancer, following promising interim data from October 28, 2026.
  • Phase 1 data from ZM008 + LOQTORZI combination trial (collaboration with Zumutor Biologics).
  • Full-year 2026 LOQTORZI revenue trajectory toward $57M-$62M guidance range.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Coherus Oncology, Inc. PRESS-RELEASE CHRS ·Originating report

Sources · 14

Hover a chip for the title
1 markets.businessinsider.com2 msn.com3 wtop.com4 msn.com5 nasdaq.com6 curetoday.com7 fiercepharma.com8 krqe.com9 nasdaq.com10 cancernetwork.com11 marketscreener.com12 marketscreener.com13 ad-hoc-news.de14 globenewswire.com